A Phase 1/2 interventional study of VC005 tablets in Non-Segmental Vitiligo, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1/2, Interventional, and Treatment
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
This study's planned enrollment of 10 is below the median of 36 across 265 interventional studies indexed under Vitiligo.
Browse Vitiligo studies →Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 35 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VC005 tablets
VC005 repeat administration for up to 24 weeks
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）
Time frame: Day1，Day28
Peak Plasma Concentration (Cmax）
Time frame: Day1，Day28
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VC005
Jiangsu vcare pharmaceutical technology co., LTD →